Skip navigation
Currently Being Moderated

Recently Medsphere was introduced to Contineo, a silicon valley startup, whose goal is the integration of mobile devices within healthcare to provide ubiquitous portable access to critical information.  In particular this company is focused on mobile (handheld) access to data, real-time alerting, secure messaging and location services.  The platform is meant to aggregate data from multiple systems and present the clinicians with a honed workflow purposefully built for the device. An extremely compelling product from a healthcare delivery perspective.

 

You may be asking, why are we talking about such a product here in the OVID blog?

 

Simple: On their own, Contineo used the open source OVID platform to build an iPod Touch/iPhone application that pulls patient data directly from OpenVista.  Their development team created the app, leveraging the OVID model to quickly create a new visualization of OpenVista patient data -- putting it literally into the hands of the clinicians that need it, right at the bedside.

 

Hugo Troche, CEO and co-Founder told us:

OVID is simple to understand and use. Yet, at the same time is powerful and highly extensible. We were able to quickly create a bridge to an OpenVistA implementation with OVID.


While Contineo's vision is to be back-end agnostic, OpenVista and OVID was a perfect starting point due to the tremendous efforts of MedSphere and the OpenVista community in providing access to a fully defined and robust system that allowed us to quickly develop our system in such a way that we did not need direct access to a production environment for the initial release. If you're an OpenVista user and would be interested in a demo, proof of concept or potential pilot, please contact us at info@contineo.us

 

Hugo was kind enough to record a quick demonstration (about 3 minutes) of the application in action -- enjoy:

 

Watch the video directly @ http://medsphere.blip.tv.

1,452 Views Tags: ovid, iphone, ipod_touch, contineo


There are no comments on this post